Articles

Choosing the Right Therapy for Patients with NSCLC

Dr. Edward Garon speaks about how differences in patient populations with lung cancer can make it difficult to interpret and act on data. Read More ›

Immunotherapies and Lung Cancer

Dr. Edward Garon shares an anecdote about an interesting NSCLC case from his practice. Read More ›

My Practice: Roles and Responsibilities

Dr. Edward Garon explains how he discusses immunotherapies with patients. Read More ›

Challenges in Managing Toxicities

Dr. Edward Garon describes how staff at his practice interacts with patients. Read More ›

Extended Letrozole Provides Little Benefit in Postmenopausal Women with Early-Stage, HR-Positive Breast Cancer

Dr. Edward Garon believes it's important to recognize that agents without efficacy are not beneficial to the patient despite low toxicity. Read More ›

Dense Breasts Up the Risk for Contralateral Breast Cancer

Although 5 years of neoadjuvant endocrine therapy improves disease-free survival in patients with early-stage breast cancer, the optimal duration of adjuvant therapy beyond 5 years has yet to be established. Results of a new study, suggesting that longer is not necessarily better, provide further insight on this topic. Read More ›

Pertuzumab Adds to PFS and Is Well Tolerated in HER2+/HR+ Advanced Breast Cancer

An evaluation of more than 200 patients with breast cancer showed a near doubling of the risk for contralateral disease with dense breast tissue. This information may help clinicians counsel patients on their personal risk and options for treatment and surveillance. Read More ›

BRCA Status Does Not Predict Outcome in Younger Patients with Breast Cancer

Adding pertuzumab to standard therapy in women with HER2+ /HR+ locally advanced or metastatic breast cancer increased PFS, with no new safety signals identified. Read More ›